Towards Personalized Treatment of MultipleMyeloma: The role of Patient-Derived Organoids

Background: Multiple myeloma (MM) occurs for ۱% of all cancers and ۱۰% of hematologic malignancies. The disease isinduced by cytogenetic abnormalities that include oncogeneinvolvement as well as gene transfer with other copy numberadjustments taking place during the later stages. Nevertheless,due to the cancer heterogeneity it becomes strenuous to developgeneralized treatment options which would be equally effectivefor each individual case. In the cancer biology studying area,patient-derived organoids (PDOs) present a hopeful option tomimic human tumor biology and explore cellular interactionswith the environment centering on tumors. Although severalcancers have yielded successful derivation of organoid models,The production of organoids derived from different cancers,despite its high value, still has a lot to improve. The currentPDO technology can also be an attractive ex vivo perspective tostudy the cancer biology of multiple myeloma.Materials and Methods: We comprehensively searched GoogleScholar and Pubmed databases using relevant keywords multiplemyeloma, organoids, patient-derived organoids, and multiplemyeloma-derived organoids. The documents were thensummarized and categorized accordingly.Results: The emergence of ۳D patient-derived MM modelssuch as Bioprinted BM MM Models and also, Matrigel Matrix-Embedded Models (Both Human Bone Marrow Organoid and۳D MM Organoid Model ) bring to light encouraging prospectsfor cultivating cancer organoids in individuals with multiplemyeloma. Such innovations boast the potential to ensure a moreaccurate depiction of microenvironment occurrence within tumors.Conclusion: The exploration of PDO technology in multiplemyeloma presents an electrifying prospect for establishing afoundation to facilitate successful MM therapy. Such progresspossesses the potential to enable medical professionals withvaluable insights into individual patient treatment options thatare optimal. Although further efforts need implementation towardsachieving tumor microenvironment simulation withinthese models, the recent improvements realized through creating۳D model representations manifest hopeful strides taskedwith producing more precise cancer models down the line.

کلیدواژه ها:

multiple myeloma ، organoids ، patient-derived organoids ، and multiple myeloma-derived organoids